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Introduction 
This paper summarizes issues related to the use of 
inhaled glucocorticoids in asthma therapy that were 
relevant to the second revision of the British Thoracic 
Society (BTS) Guidelines for asthma therapy. These 
include the place of new glucocorticoids and their use 
in asthma, based on evidence available since the last 
revision of the Guidelines in 1993. The optimal use of 
inhaled glucocorticoid and the importance of delivery 
systems is also discussed. Safety issues were discussed 
specifically by Donald Lane and are not included in 
this article. 
Fluticasone Propionate 
Inhaled fluticasone propionate (FP) has become 
available in the U.K. since the last revision of the 
BTS Guidelines. It is claimed that FP has an 
improved risk/benefit compared with other inhaled 
steroids. Its clinical efficacy and safety have now been 
documented extensively (1). 
Fluticasone propionate is a fluorinated glucocorti- 
coid with high topical potency and increased 
lipophilicity, which has a high affinity for the gluco- 
corticoid receptor (2,3). It is metabolized by first-pass 
hepatic metabolism, so that there is ~1% oral bio- 
availability (4). However, as with all other inhaled 
steroids, it is absorbed from the lung into the 
systemic circulation (5,6). 
The two important considerations with FP are its 
potency and its systemic absorption, in comparison 
with beclomethasone dipropionate (BDP) and 
budesonide. The risk: benefit ratio of inhaled steroids 
is determined by the topical potency (airway anti- 
inflammatory effect) and systemic effects (7). 
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TOPICAL POTENCY 
In the McKenzie skin vasoconstrictor test in 
humans, FP is approximately twice as potent as BDP 
and budesonide (2) although another study using a 
more precise analysis shows similar potency (8). 
Fluticasone propionate is more potent than BDP and 
budesonide in inhibiting T-lymphocyte proliferation 
(9). Both FP and budesonide have a longer dwell time 
in lung tissue than BDP in airway tissues (10). 
Several clinical studies have compared FP with 
BDP, and the data is consistent with approximately 
twice the potency. However, it is difficult to be 
precise, as it is hard to establish dose-response effects 
of inhaled steroids in asthma (see below). 
Studies where FP has been compared with BDP 
Lundback et al.: Double-blind parallel group 
multi-centre design in 585 asthmatics compared FP 
0.5 mg day - ’ via Diskhaler or pressurized metered 
dose inhaler (pMD1) with BDP 1 mg day- ’ via 
pMD1 for 6 weeks (11). Both formulations of FP 
gave equivalent control to BDP. 
Fabbri et al.: Double-blind parallel group multi- 
centre study in 142 patients with moderate to severe 
asthma for 12 months. FP 1.5 mg day ~ ’ via pMD1 
gave significantly better control [symptoms, peak 
expiratory flow, lung function tests (LFTs)] than 
BDP 1.5 mg day- i via pMD1 (12). 
Dahl et al.: Double-blind parallel group multi- 
centre study in 672 patients for 4 weeks (13). Dose 
ranging study of FP (0.1, 0.2, 0.4, 0.8 mg day - ’ 
via pMD1) compared with BDP (0.4 mg day- ’ via 
pMD1) showed a dose-related improvement in LFTs, 
and FP was approximately twice as potent as BDP. 
Barnes et aZ.: Double-blind parallel group multi- 
centre study in 154 patients with severe asthma for 
6 weeks (14). FP 1 mg pMD1 gave similar control of 
asthma to BDP 2 mg via pMD1. 
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Gustafsson et al.: Double-blind parallel group 
multi-centre study in 398 children (4-19 years) (15). 
FP 0.2 mg via pMD1 gave similar control to BDP 
0.4 mg day - ‘. 
Leblanc et al.: Double-blind parallel group multi- 
centre study in 261 patients with mild to moderate 
asthma (16). FP 0.4 mg day - i via pMD1 gave 
similar control to BDP 0.2 mg day - i via pMD1. 
Lundback et aZ.: Double-blind parallel group 
multi-centre study in 296 patients with mild to 
moderate asthma (17). Comparison of FP 0.2 mg via 
pMD1 and Diskhaler showed similar efficacy. 
Studies where FP has been compared with budesonide 
Connolly et al.: Open parallel group study in 
general practice of 189 patients with mild asthma for 
8 weeks (18). FP 0.2 mg via Diskhaler gave similar 
control to 0.4 mg budesonide via Turbohaler. 
Ayres et al.: Double-blind parallel group study in 
671 patients with severe asthma for 6 weeks (19). FP 
1 mg and 2 mg via pMD1 gave greater improvement 
in some parameters than budesonide 1.6 mg via 
pMD1, although differences were small and unlikely 
to be relevant clinically. 
Langdon et af.: Open parallel group study in 157 
patients in general practice, comparing FP 0.2 mg via 
pMD1 with budesonide 0.4 mg via pMD1. There 
were no significant differences in symptoms or lung 
function. 
SYSTEMIC ABSORPTION 
Fluticasone propionate is well tolerated and several 
studies have been designed to investigate systemic 
effects, using hypothalamo-pituitary axis function, 
markers of bone metabolism and knemometry. 
The oral bioavailability of budesonide is 11% (20), 
whereas that for FP is estimated to be 1%. Beclo- 
methasone dipropionate and its active metabolite 
BMP are absorbed to a much greater extent because 
there is less first-pass hepatic metabolism. In view of 
the efficient first-pass metabolism of budesonide and 
FP, absorption from the lung accounts for most of 
the systemic effects; both FP and budesonide are 
absorbed unchanged into the systemic circulation. 
The inhaler delivery device which determines the 
amount of inhaled steroid reaching the respiratory 
tract thus becomes an important determinant of 
systemic absorption, and it is important to consider 
drug delivery devices when comparing inhaled 
steroids. 
Several markers of systemic activity of inhaled 
steroids have been used to compare inhaled steroids 
and these vary in sensitivity. In large multi-centre 
trials. it is difficult to make sensitive and accurate 
measurements. Results are somewhat conflicting with 
high doses. Comparison between FP and BDP given 
by pMD1 have shown no major differences at a dose 
of 1.5 mg day - ’ in terms of plasma cortisol, urinary 
free cortisol and tetracosactrin response (12), but, in 
another study, FP 1 mg day- ’ had slightly less effect 
on plasma cortisol than BDP 2 mg day - ’ (14). A 
U.S.A. multi-centre study in 331 patients with mild to 
moderate asthma showed that FP in doses of 0.05, 
0.2 and 1 mg day - i via pMD1 had no effect on 
morning cortisol of tetracosactrin-stimulated cortisol 
although, at the highest dose, there was a reduction 
in urinary cortisol (21). However, in another study 
there was significant suppression of plasma cortisol 
and ACTH with FP 2 mg day- ‘, whereas no sup- 
pression was seen iYith BDP 1.6 mg day- i (22). 
Fluticasone propionate via the Diskhaler has been 
shown to have a higher systemic potency when given 
in repeated doses than after a single dose, which has 
not been reported previously for an inhaled steroid 
(23). In a small study of normal subjects, both FP 
0.8 mg and 1.6 mg day- ’ via Turbohaler and FP 
0.75 and 1.5 mg via Diskhaler for 7 days had no effect 
on morning plasma cortisol, but both suppressed 
post-tetracosactrin cortisol levels (24). There were 
no differences between drugs or between doses. In 
view of the increased deposition of steroid by the 
Turbohaler compared to the Diskhaler, this suggests 
a greater systemic absorption of FP. In children, 
knemometry studies have demonstrated that BDP 
causes a dose-related inhibition of short-term growth; 
this is significantly less with both budesonide and 
FP (5). 
RECOMMENDATIONS 
There is reasonably convincing evidence that FP 
has a greater potency than BDP or budesonide, 
which is estimated to be approximately 2:l. Studies 
of systemic absorption suggest that when equipotent 
doses of budesonide and FP are used, systemic 
absorption is similar. This indicates that the risk: 
benefit ratio for FP and budesonide are probably 
similar and both are better than BDP. Thus, FP 
should be included in the Guidelines as an alternative 
inhaled steroid at half the doses recommended 
for BDP and budesonide. However, the inhaler 
device used is an important determinant of 
systemic availability, making it difficult to make 
simple dose comparisons between different steroids 
(see below). 
Nebulized Budesonide 
Nebulized budesonide suspension has been used in 
the treatment of children and adults. In a double- 
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blind study in children (6-15 years), nebulized 
budesonide (1, 2, 4 mg day- ‘) gave a dose-related 
improvement in daytime and night-time symptoms, 
and 0.4 mg via a pMD1 gave similar improvement to 
1 mg via nebulizer (25). In a double-blind placebo- 
controlled parallel group study of 36 children under 
5 years with severe steroid-dependent asthma, 
budesonide 1 mg b.d. via nebulizer gave improved 
control compared to placebo, and there was a signifi- 
cant reduction in daily dose of oral prednisolone over 
8 weeks (26). Similar results were obtained in a study 
of 40 infants (6-30 months) given 2 mg nebulized 
budesonide compared with placebo over 12 weeks (27). 
In a multi-centre double-bind parallel group placebo- 
controlled study in 67 children (640 months), there 
was a significant reduction in the number of asthma 
exacerbations with nebulized budesonide 2 mg day - ’ 
compared with 0.5 mg day- ’ (28). 
Although nebulized budesonide has been available 
for some time, there is no data from controlled 
studies in adults. In an open study of nebulized 
budesonide in 18 steroid-dependent patients (19-62 
years), there was a steroid-sparing effect of 
48mgday-’ nebulized budesonide (29). Fourteen of 
18 patients taking >7*5 mg day - i prednisolone were 
able to stop the oral steroids completely. In a subse- 
quent multi-centre open study in 42 adults with 
steroid-dependent asthma, nebulized budesonide 
1 mg b.d. replaced budesonide in the same dose given 
by pMD1 (30). There was a reduction in oral pred- 
nisolone requirement by approximately 50%. Open 
studies of steroid reduction are difficult to interpret 
because of a large placebo effect. It is not certain 
whether nebulized budesonide in high doses has sys- 
temic effects that are less than those with oral steroids. 
RECOMMENDATIONS 
Nebulized budesonide is clearly effective in con- 
trolling severe asthma in children ~3 years and 
appears to be well tolerated. Above the age of 3 
years, alternative delivery systems are likely to be just 
as effective. 
In adults, there is no data available from con- 
trolled trials to indicate that nebulized budesonide is 
superior to high doses of inhaled steroids given by 
dry powder of MD1 plus spacer systems. The high 
cost of nebulized budesonide argues against its 
use, until such evidence is available. Nebulized 
budesonide should be an option for steroid- 
dependent asthmatics (Step 5) and may be useful for 
reducing the maintenance dose of oral glucocorti- 
coids. Controlled studies are needed to assess the 
therapeutic ratio of nebulized budesonide in patients 
with severe asthma. 
Risk of Systemic Side-effects With Different 
Preparations 
All currently available inhaled steroids are 
absorbed systematically from the lungs (56). The 
detection of systemic effects depends on the sensi- 
tivity of the indices used to detect the systemic effect. 
Thus, a single measurement of plasma cortisol is 
less sensitive that 24 h urinary cortisol or a post- 
tetracosactrin cortisol. Repeated measurements of 
plasma cortisol over a 24-h period may be the most 
sensitive index. Similarly, measurement of osteo- 
calcin is more sensitive than measurement of bone 
alkaline phosphatase and urinary calcium excretion 
in detecting the effect of steroids on bone metab- 
olism. Currently available inhaled steroids have been 
assessed carefully and it is clear that the steroid itself 
and the inhaler delivery system used have marked 
effects on systemic absorption. 
EFFECT OF DELIVERY SYSTEMS 
Amongst inhaled steroids, budesonide and FP 
have fewer systemic effects than BDP for equally 
effective anti-asthma doses. Systemic effects are 
reduced by the use of a large volume spacer with an 
MD1 or by mouth washing with a dry powder inhaler 
for BDP and budesonide (31,32). For FP, there is 
virtually no oral bioavailability as first-pass hepatic 
metabolism is almost complete. However, all three 
inhaled steroids are absorbed from the lungs and 
the efficiency of the delivery system will determine 
the dose that reaches the respiratory tract and the 
systemic circulation. The Turbohaler delivers 
approximately twice as much budesonide to the lung 
as MD1 (33), and this is reflected by the fact that the 
dose of budesonide needed for asthma control is 
approximately half when a Turbohaler is used, com- 
pared to the MD1 device in children (34,35) and 
adults (36). For this reason, systemic effects with 
budesonide will be greater when the Turbohaler is 
used. This suggests that the dose of budesonide 
should be approximately half when a Turbohaler is 
used. By contrast, the Diskhaler appears to deliver 
less inhaled steroid to the lung than an MD1 device. 
Overall, inhaled steroids produce no clinically rel- 
evant systemic effects at the doses that most patients 
require for asthma control. There is no convincing 
evidence that inhaled steroids, even in high doses 
(2 mg day - ‘), have effects on density, growth in 
children or adrenal insufficiency, although further 
long-term follow-up studies are needed. However, as 
budesonide and FP produce less systemic effects than 
BDP, these steroids are preferable in children, and in 
adults taking > 1 mg day - ‘. 
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Dose Response to Inhaled Steroids 
It has often proved difficult to demonstrate clear 
dose responses to the anti-asthma effect of inhaled 
steroids in controlled clinical trials although, in clini- 
cal practice, improved asthma control can often be 
achieved by increasing the dose of inhaled steroids. 
This paradox may be explained by several factors 
that result in a flat dose-response curve. In clinical 
trials, patients with stable asthma are often selected 
and these patients may already be controlled opti- 
mally with inhaled steroids, so that an increase in 
dose will not provide any further improvement. How- 
ever, if asthma deteriorates, a higher dose of inhaled 
steroid may be more effective, presumably because 
there is a greater amount of inflammation to reverse. 
The dose response to inhaled steroids may be 
relatively flat as higher doses are reached, so that 
doubling the dose may not give much improvement 
in asthma control. There is some evidence that 
patients with more severe asthma may be more 
resistant to steroids (possibly due to the inhibitory 
effects of cytokine-activated transcription factors on 
glucocorticoid receptors). It is also difficult to moni- 
tor steroid responses in asthma accurately, since any 
improvement in asthma control may occur slowly 
and the degree of improvement varies between 
patients. This makes it difficult to compare different 
steroids and to study the dose response of an individ- 
ual steroid, as large numbers of patients are needed 
with a severity great enough to allow a dose response 
to be observed. What is needed is an objective 
measurement of steroid efficacy that is not affected 
by bronchodilator therapy or confounded by lung 
function. Measurements, such as induced sputum to 
assess inflammatory cells and mediators, and exhaled 
nitric oxide are being explored currently. 
Earlier Intervention With Inhaled Steroids 
Inflammation of the airways is present even in 
patients with mild episodic asthma (37). This has 
suggested that inhaled steroid should be introduced 
at an earlier stage in asthma therapy. The rationale 
for this is that early control of inflammation may 
prevent the development of irreversible changes in 
airway function and the subsequent development of 
more severe asthma. There is also a hope that early 
control of asthma may alter the natural history of 
the disease. 
There is some evidence that early treatment with 
inhaled steroids may result in improved lung func- 
tion, compared with other treatments. In a double- 
blind parallel group study, patients treated with 
inhaled budesonide for 2 yr had better lung function 
than patients treated with terbutaline (38). After 2 yr, 
the group treated with terbutaline were switched 
to budesonide and had less improvement in lung 
function than was seen with the group treated with 
budesonide from the time of diagnosis, suggesting 
that some irreversible changes had occurred within 
the 2 yr since symptoms and treatment began (39). 
An uncontrolled observational study showed that 
children treated with inhaled steroids had better lung 
function than children treated with other treatments 
(34). The longer after diagnosis of asthma that 
inhaled steroids were introduced, the less the 
improvement in lung function. Similar results have 
been described in adults, with the greatest improve- 
ment in lung function seen when inhaled steroids 
were introduced within 6 months of diagnosis and a 
progressive fall-off in the improvement was possible 
as institution of inhaled steroids was delayed by up to 
10 yr (40). 
These studies suggest that inhaled steroids should 
be introduced as early as possible. However, against 
this is the expense involved and the possible risk of 
adverse effects with long-term therapy. Long-term 
controlled trials are needed before this treatment 
approach can be justified. Such a long-term study in 
adults and children, funded by the NHS Executive, is 
currently entering a pilot stage. 
Inhaled steroids should be introduced when 
patients need to use a &agonist inhaler more than 
three times a week. This is in line with the Inter- 
national Guidelines for Asthma Therapy (42) and 
would be a change from the current BTS recommen- 
dation of daily use of inhaled steroids when the 
patient uses a &antagonist once daily. 
Start With High Dose and Decrease? 
Current Guidelines suggest that inhaled steroids 
should be started in a low dose and increase pro- 
gressively until asthma control is achieved. This is 
contrary to clinical practice and to common sense. As 
inhaled steroids have a slow onset of action, patients 
who are not controlled lose confidence in the treat- 
ment and this is likely to decrease compliance. It 
would be more sensible to start at a dose that is likely 
to be effective and then reduce to the minimal dose 
needed to maintain control. This approach is logical 
in the light of our current understanding of the mode 
of action of steroids. 
Steroids activate glucocorticoid receptors which 
act as functional antagonists of transcription factors 
that regulate increased transcription of genes, such 
as inflammatory cytokines and enzymes in asthma. If 
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there is active inflammation in the airways, the high 
level of transcription factors bind to glucocorticoid 
receptors, so that steroids are less effective and 
cannot effectively gain control of the inflammatory 
response. Higher doses of steroids overcome this by 
blocking the activated transcription factors, so that 
more glucocorticoid receptors are available for 
blocking the inflammatory response. Control can 
then be maintained with lower doses of steroids. 
Although there are no clinical trials comparing 
the two approaches of high-to-low vs. low-to-high 
inhaled steroids, there are studies which demonstrate 
that the dose of inhaled steroid can be reduced once 
control is achieved (34,39). 
RECOMMENDATION 
Most patients should be started in inhaled steroids 
in a dose of 400,ug b.d. and should be treated with 
this dose for at least 3 months (as this is a time when 
most of the benefit of the inhaled steroid is obtained). 
The dose of inhaled steroid should then be reduced 
according to a simple step-down regime (see below). 
In a few patients, the initial dose of steroids may be 
too low and it may be necessary to increase the dose. 
In patients with severe asthma, it may be necessary to 
start treatment with oral steroids in order to obtain 
control initially; inhaled steroids should be started at 
the same time. 
Increasing Inhaled Steroids at the Onset of 
Deterioration 
Most guidelines have recommended that patients 
should double the dose of inhaled steroid temporarily 
if their asthma deteriorates (with a fall in PEF of 
25-30%), or at the first sign of an upper respiratory 
tract infection. There have been no formal trials to 
assess whether this is effective. In a recent multi- 
centre study in general practice, 413 patients who 
developed a deterioration in asthma that required 
oral steroids, but not hospitalization, were shown to 
respond as well to FP 2 mg day - i compared with a 
course of oral steroids (prednisolone 40 mg day ~ ‘, 
reducing by 5 mg every 2 days) (42). 
Controlled studies are needed to answer this ques- 
tion before the recommendations are changed. These 
studies would be relatively easy to conduct and could 
be placebo controlled. 
When to Step Down 
Although stepping up inhaled steroids has been 
emphasized in the BTS Guidelines, stepping down, 
once asthma is controlled, has not been emphasized 
enough. The result is that many patients are over- 
treated with inhaled steroids. This is apparent in 
most trials that have attempted reduction in inhaled 
steroids. Emphasis on stepping down will be even 
more important if the start-high regime is adopted. 
Any reduction in inhaled steroids should be slow, 
as patients deteriorate at different rates when steroids 
are withdrawn (39,43,44). Thus, in some patients, a 
rapid fall in lung function and increase in symptoms 
is observed, whereas, in other patients, the deterior- 
ation is only apparent after weeks. Reduction in 
inhaled steroids should be monitored by symptoms, 
&agonist use and PEF. Reductions should take 
place every 3 months by reducing the dose of inhaled 
steroid by approximately 25% at each step. Some 
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